Please join us for our next General Membership meeting on August 7th from 8-9PM. Adam Rzetelny, Ph.D., will present information about Brixadi, the recently approved extended-release subcutaneous buprenorphine injection.
Dr. Adam Rzetelny is a Medical Science Liaison at Braeburn Pharmaceuticals. He is a licensed clinical psychologist with nearly 20 years of clinical and research experience in psychiatry and Substance Use Disorders. He has authored articles and presented on topics including destigmatizing SUD, treating SUD in special populations, the clinical use of toxicology, and pharmacogenetics. Dr. Rzetelny was born and raised in New York City. He earned his bachelors at University of Georgia, his doctoral degree at Southern Illinois University, Carbondale, and did post-doctoral work at Memorial Sloan-Kettering Cancer Center in NYC. He resides in New Jersey with his two young children.
Please check your email or reach out to us for the link to join. We look forward to seeing you on Monday, August 7th!
